Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | SVP - Finance & PFO | February 06, 2020 | February 10, 2020 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | CHIEF FINANCIAL OFFICER | February 04, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date February 06, 2020 · Filed February 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.72 · Expires 2030-02-06 | Direct | 25,000 |
Reported balance
After 2020-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-06 · Grant · Acquired 25,000 · Balance 25,000 F1: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.89 · Expires 2030-02-10 | Direct | 3,000 |
Reported balance
After 2020-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-10 · Grant · Acquired 3,000 · Balance 3,000 F2: This option represents a right to purchase a total of 3,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F2: This option represents a right to purchase a total of 3,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
Taysha Gene Therapies, Inc.
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,442,131 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Sale · Disposed 1,655 · Balance 1,442,131 F1: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 6, 2026 21:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 1,655 | $4.52 | $7,480.60 |
DisclosureSEC source: 0001793412-26-000012 · form4-02062026_040223.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,442,131 F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 23,849 | $4.61 | $109,943.89 |
DisclosureSEC source: 0001793412-26-000008 · form4-01272026_040101.xml · nonDerivative · entry 2 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,443,786 F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 78,968 | $4.75 | $375,098.00 |
DisclosureSEC source: 0001793412-26-000008 · form4-01272026_040101.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,467,635 F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 231,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001793412-26-000002 · form4-01142026_040105.xml · derivative · entry 2 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,000 Underlying: Common Stock · 231,000 shares Expires 2036-01-12 F2 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:45 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 359,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001793412-26-000002 · form4-01142026_040105.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,546,603 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 54,491 | $2.85 | $155,299.35 |
DisclosureSEC source: 0001415889-25-022749 · form4-08222025_040804.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,187,603 F1 · shares: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Tax withholdingCommon Stock | 29,843 | $1.69 | $50,434.67 |
DisclosureSEC source: 0001415889-25-007997 · form4-03132025_040301.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,242,094 F1 · kind: Represents shares withheld by the Issuer to satisfy the tax withholding obligations triggered by the vesting and settlement of restricted stock units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:31 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 431,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001415889-25-000595 · form4-01032025_100118.xml · derivative · entry 2 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,000 Underlying: Common Stock · 431,000 shares Expires 2035-01-02 F2 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:31 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 431,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000595 · form4-01032025_100118.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,271,937 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:42 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | Tax withholdingCommon Stock | 1,288 | $1.51 | $1,944.88 |
DisclosureSEC source: 0001415889-24-002809 · form4-02062024_090255.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840,937 F1 · kind: Represents shares withheld by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:43 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 590,413 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000811 · doc4.xml · derivative · entry 2 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,413 Underlying: Common Stock · 590,413 shares Expires 2034-01-02 F2 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:43 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 590,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000811 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 842,225 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:50 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 187,582 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058977 · doc4.xml · derivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,582 Underlying: Common Stock · 187,582 shares Expires 2033-12-14 F1 · derivative.exercise_date: The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 33,000 | $2.33 | $76,890.00 |
DisclosureSEC source: 0001209191-23-047323 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,042 F1 · kind: This sale was effected pursuant to a mandatory "sell to cover" arrangement adopted by the Reporting Person on May 26, 2023 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.185 to $2.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:12 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 6,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033681 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,042 F1 · shares: Represents a performance restricted stock unit ("PRSU") award. The PRSUs were awarded on February 2, 2023 by the Compensation Committee (the "Compensation Committee") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The PRSUs covered by this report vested upon certification. F2 · price: Each PRSU represented a contingent right to receive one share the Issuer's common stock. Read SEC document |
| May 31, 2023 Filed Apr 10, 2025 20:15 UTC Amendment | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 12,462 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001415889-25-010539 · form4a-04102025_040408.xml · derivative · entry 1 Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,462 Underlying: Common Stock · 12,462 shares Expires 2033-02-02 F1 · derivative.exercise_date: The option was awarded on February 2, 2023 by the Compensation Committee (the "Compensation Committee") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The shares underlying the option covered by this report vested upon certification. This option was inadvertently omitted for the original Form 4. Read SEC document |
| February 02, 2023 Filed Feb 7, 2023 02:12 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 149,900 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-23-007396 · doc4.xml · derivative · entry 3 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,900 Underlying: Common Stock · 149,900 shares Expires 2033-02-02 F4 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 02, 2023 Filed Feb 7, 2023 02:12 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 37,384 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-23-007396 · doc4.xml · derivative · entry 2 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,384 Underlying: Common Stock · 37,384 shares Expires 2033-02-02 F3 · derivative.exercise_date: 24,923 shares underlying the option shall vest 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter. The remaining shares underlying the option, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 02, 2023 Filed Feb 7, 2023 02:12 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 18,691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-007396 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,812 F1 · shares: Represents a restricted stock unit ("RSU") award. 12,461 RSUs shall vest 25% on each of February 2, 2024, February 2, 2025, February 2, 2026 and February 2, 2027. The remaining RSUs, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share the Issuer's common stock. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 20:47 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 3,325 | $3.47 | $11,537.75 |
DisclosureSEC source: 0001209191-22-047353 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,121 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 00:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 9,717 | $3.50 | $34,009.50 |
DisclosureSEC source: 0001209191-22-047097 · doc4.xml · nonDerivative · entry 3 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,446 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.71 inclusive. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 00:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 11,482 | $3.75 | $43,057.50 |
DisclosureSEC source: 0001209191-22-047097 · doc4.xml · nonDerivative · entry 2 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,163 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.85 inclusive. Read SEC document |
| August 18, 2022 Filed Aug 23, 2022 00:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 7,476 | $3.87 | $28,932.12 |
DisclosureSEC source: 0001209191-22-047097 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,645 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $3.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:27 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001209191-22-023863 · doc4.xml · derivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-04-06 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on April 6, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:18 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001209191-22-013160 · doc4.xml · derivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| August 20, 2021 Filed Aug 20, 2021 21:52 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 2,094 | $17.14 | $35,891.16 |
DisclosureSEC source: 0001209191-21-052824 · doc4.xml · nonDerivative · entry 5 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,121 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.25 inclusive. Read SEC document |
| August 20, 2021 Filed Aug 20, 2021 21:52 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 9,746 | $16.70 | $162,758.20 |
DisclosureSEC source: 0001209191-21-052824 · doc4.xml · nonDerivative · entry 4 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,215 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.03 to $17.02 inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 21:52 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 613 | $17.11 | $10,488.43 |
DisclosureSEC source: 0001209191-21-052824 · doc4.xml · nonDerivative · entry 3 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,961 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.12 inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 21:52 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 9,354 | $16.43 | $153,686.22 |
DisclosureSEC source: 0001209191-21-052824 · doc4.xml · nonDerivative · entry 2 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,574 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.04 to $17.03 inclusive. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 21:52 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | SaleCommon Stock | 11,193 | $17.35 | $194,198.55 |
DisclosureSEC source: 0001209191-21-052824 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,928 F1 · kind: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.95 to $17.825 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6). Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 01:20 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004571 · doc4.xml · derivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-01-19 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:08 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 331,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052110 · doc4.xml · nonDerivative · entry 1 Alam Kamran · CIK 0001793412 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,121 F1 · shares: The shares underlying the RSU vest in 4 equal annual installments on each of August 17, 2021, August 17, 2022, August 17, 2023 and August 17, 2024, subject to the Reporting Person's continuous service as of each such vesting date. F2 · price: Each RSU represents a contingent right to receive one share the Issuer's common stock. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 22:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $23.89 | $0.00 |
DisclosureSEC source: 0001209191-20-008006 · doc4.xml · derivative · entry 2 Alam Kamran · CIK 0001793412 · SVP - Finance & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2030-02-10 F2 · derivative.exercise_date: This option represents a right to purchase a total of 3,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 22:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $22.72 | $0.00 |
DisclosureSEC source: 0001209191-20-008006 · doc4.xml · derivative · entry 1 Alam Kamran · CIK 0001793412 · SVP - Finance & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001209191-19-055529 · doc4.xml · derivative · entry 1 Alam Kamran · CIK 0001793412 · SVP - Finance & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-11-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, 1/3 of which will become fully vested and exercisable on November 4, 2020, with the remaining 2/3 vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.